Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2022 Conference scheduled for January 10-13, 2022. The on-demand presentation will be accessible starting January 10, 2022, at 7:00 a.m. E.T. on the company’s website under the 'Events & Presentations' section. Dynavax is a biopharmaceutical firm specializing in developing vaccines, including HEPLISAV-B®, which is approved for preventing hepatitis B infections in adults.

EMERYVILLE, Calif., Jan. 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022.

The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, seasonal influenza and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2022-conference-301454785.html

SOURCE Dynavax Technologies

FAQ

What is Dynavax presenting at the H.C. Wainwright Virtual BioConnect 2022 Conference?

Dynavax Technologies will have CEO Ryan Spencer presenting at the H.C. Wainwright Virtual BioConnect 2022 Conference from January 10-13, 2022.

When will Dynavax's presentation be available for viewing?

The on-demand presentation from Dynavax will be available starting January 10, 2022, at 7:00 a.m. E.T.

What is Dynavax's stock symbol?

Dynavax Technologies is listed under the stock symbol DVAX.

What is the main focus of Dynavax Technologies?

Dynavax Technologies focuses on developing and commercializing vaccines to protect against infectious diseases.

What products does Dynavax have on the market?

Dynavax’s first commercial product is HEPLISAV-B®, a hepatitis B vaccine approved for adults.